FTY720 inhibits S1P-mediated endothelial healing: relationship to S1P1-receptor surface expression
- PMID: 18402775
- DOI: 10.1016/j.bbrc.2008.03.144
FTY720 inhibits S1P-mediated endothelial healing: relationship to S1P1-receptor surface expression
Abstract
The phosphorylated derivative of the immunosuppressant FTY720 interacts with and modulates the function of sphingosine-1-phosphate (S1P)-receptors. We observed a significant reduction of endothelial surface binding of a S1P(1)-specific antibody after FTY720 treatment of 6h and longer, which was associated with a reduced healing after mechanic injury, impaired angiogenesis and enhanced adhesion molecule expression. FTY720 (5h) had no impact on the expression of S1P(1)- or S1P(3)-encoding transcripts. Notably, pre-treatment of cells with FTY720 for only 30min, which did not reduce S1P(1) surface expression, inhibited the rapid S1P- and SEW2871- (a S1P(1) agonist) induced cortical actin formation and cell migration. FTY720 was effective at concentrations as low as 5nM. FTY720 at therapeutic concentrations may be harmful by impairing important endothelial functions. Interestingly, FTY720 inhibited endothelial actin remodelling and cell migration without decreasing S1P(1) surface expression.
Similar articles
-
The immunosuppressant FTY720 inhibits tumor angiogenesis via the sphingosine 1-phosphate receptor 1.J Cell Biochem. 2007 May 1;101(1):259-70. doi: 10.1002/jcb.21181. J Cell Biochem. 2007. PMID: 17203465
-
Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization.Cancer Res. 2006 Jan 1;66(1):221-31. doi: 10.1158/0008-5472.CAN-05-2001. Cancer Res. 2006. PMID: 16397235
-
FTY720 modulates human oligodendrocyte progenitor process extension and survival.Ann Neurol. 2008 Jan;63(1):61-71. doi: 10.1002/ana.21227. Ann Neurol. 2008. PMID: 17918267
-
New players on the center stage: sphingosine 1-phosphate and its receptors as drug targets.Biochem Pharmacol. 2008 May 15;75(10):1893-900. doi: 10.1016/j.bcp.2007.12.018. Epub 2008 Jan 5. Biochem Pharmacol. 2008. PMID: 18321471 Review.
-
Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus.Cell Mol Immunol. 2006 Feb;3(1):11-9. Cell Mol Immunol. 2006. PMID: 16549044 Review.
Cited by
-
Prolonged exposure to sphingosine 1-phosphate receptor-1 agonists exacerbates vascular leak, fibrosis, and mortality after lung injury.Am J Respir Cell Mol Biol. 2010 Dec;43(6):662-73. doi: 10.1165/rcmb.2009-0345OC. Epub 2010 Jan 15. Am J Respir Cell Mol Biol. 2010. PMID: 20081052 Free PMC article.
-
A case of posterior reversible encephalopathy syndrome associated with gilenya(®) (fingolimod) treatment for multiple sclerosis.Front Neurol. 2015 Mar 4;6:39. doi: 10.3389/fneur.2015.00039. eCollection 2015. Front Neurol. 2015. PMID: 25788891 Free PMC article.
-
FTY-720P Suppresses Osteoclast Formation by Regulating Expression of Interleukin-6 (IL-6), Interleukin-4 (IL-4), and Matrix Metalloproteinase 2 (MMP-2).Med Sci Monit. 2016 Jun 26;22:2187-94. doi: 10.12659/msm.896690. Med Sci Monit. 2016. PMID: 27344392 Free PMC article.
-
Fingolimod (FTY720-P) Does Not Stabilize the Blood-Brain Barrier under Inflammatory Conditions in an in Vitro Model.Int J Mol Sci. 2015 Dec 10;16(12):29454-66. doi: 10.3390/ijms161226177. Int J Mol Sci. 2015. PMID: 26690412 Free PMC article.
-
Pharmacological relevance and potential of sphingosine 1-phosphate in the vascular system.Br J Pharmacol. 2011 Jul;163(6):1140-62. doi: 10.1111/j.1476-5381.2011.01260.x. Br J Pharmacol. 2011. PMID: 21309759 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources